{"url_path":"/sec/tcrx/8-k/2026-06-22/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1783328/0001193125-26-276693-index.html","accession_number":"0001193125-26-276693","cik":"0001783328","ticker":"TCRX","issuer_name":"TScan Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1783328/0001193125-26-276693-index.html","primary_entity_key":"0001783328","primary_entity_name":"TScan Therapeutics, Inc."},"word_count":465,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\nOn June 22, 2026, the Company provided an update on its heme malignancies clinical program, including initial data from Cohort C of the ongoing ALLOHA™ Phase 1 study evaluating TSC-101, generated with the commercial-ready manufacturing process, in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation. Key data highlights are set forth below.\n\n \n\n \n•\n \n\n19 patients were enrolled in Cohort C:\n\n \n\n \n•\n \n\n~90% manufacturing success rate (17/19) with commercial-ready process\n\n \n\n \n•\n \n\n14/19 patients went to transplant and received their first infusion of TSC-101\n\n \n\n \n•\n \n\n10/14 patients have received their planned second infusion, and 1/14 patients received a third infusion\n\n \n\n \n•\n \n\n3/19 patients did not proceed to transplant due to clinical reasons\n\n \n\n \n•\n \n\nChimerism data as observed by high sensitivity NGS assay (Alloheme) with assay cut-off of 0.2%:\n\n \n\n \n•\n \n\n11 of 14 patients achieved complete donor chimerism within ~3 weeks of receiving their first infusion of TSC-101 and 2 of the remaining 3 patients are approaching complete donor chimerism\n\n \n\n \n•\n \n\nOne patient with TP53 mutated AML remained in complete donor chimerism 6 months post-HCT\n\n \n•\n \n\nTSC-101 infusions were generally well-tolerated, safety was consistent with Cohort A, and observed adverse events were consistent with post-HCT adverse events.\n\nForward-Looking Statements\n\nThis Current Report on Form 8-K contains forward-looking statements that are based on the Company’s beliefs and assumptions and on information currently available to the Company on the date of this Current Report. These forward-looking statements involve substantial risks and uncertainties. Any statements in this Current Report on Form 8-K other than statements of historical fact, including statements about the Company’s future expectations, plans and prospects, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s financial and operating results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including the factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company’s views only as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law even if new information becomes available in the future."}